FDA approval

Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS

The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq),Ā a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for treating adults with multiple sclerosis (MS). The approval covers all the same indications as the original medication, including relapsing forms of MS ā€” namely…

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus

The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion…

MS News that Caught My Eye Last Week: Reaction to SPMS DMT Approval, Ozanimod’s FDA Application, Caregiving Partnerships, a New Preventive Medication?

MS Patient Groups React Favorably to Mayzent Approval, But Question Therapyā€™s Price Tag The approval of this medication is very good news. However, as the headline indicates, it comes with a relatively hefty cost. It’s approved for active secondary progressive multiple sclerosis (SPMS), and many of us have SPMS…

Diplomat Pharmacy Chosen to Dispense Ocrevus to MS Patients Across US

Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., has been selected to dispenseĀ Ocrevus (ocrelizumab), a limited-distribution drug,Ā to people withĀ relapsingĀ  andĀ primary progressive multiple sclerosis. Ocrevus was approved by the U.S. Food and Drug Administration on March 28, becoming the first therapy approved for both RMS and…